Coursera Inc. (NYSE: COUR): The Buy rating at Truist Financial was reduced to Hold, and the analyst cut the $17.50 price target to $12. The consensus target is $18.27 for now. The stock closed on Monday at $11.31, which was down almost 7% on the day.
Dominion Energy Inc. (NYSE: D): BofA Securities trimmed its $53 target price to $52 and kept an Underperform rating. The consensus target is higher at $66.08. The stock closed on Monday at $56.33.
Driven Brands Holdings Inc. (NASDAQ: DRVN): Stifel lowered its $45 price target on the Buy-rated stock to $40. That compares with the $38.10 consensus target and Monday’s closing print of $28.35.
FTAI Aviation Ltd. (NASDAQ: FTAI): Stifel raised its $21 target price on the Buy-rated company to $30. The consensus target is $28.17. The closing share price on Monday was $25.78.
Heico Corp. (NYSE: HEI): Jefferies reiterated a Buy rating with a $205 target price. The consensus target of $171.87 is lower than Monday’s close at $174.67.
Intuit Inc. (NASDAQ: INTU): Oppenheimer reiterated an Outperform rating. Its $476 target price is less than the $483.13 consensus target. The stock closed on Monday at $421.62.
NetEase Inc. (NASDAQ: NTES): though BofA Securities lowered its $122 target price to $114, it maintained a Buy rating on the stock. The consensus target is $108.72. Shares closed on Monday at $78.98.
Nomad Foods Ltd. (NYSE: NOMD): Goldman Sachs upgraded the shares from Neutral to Buy with a $21 target price. The consensus target is $22.59. Monday’s $18.86 close was up over 8% for the day despite earnings and revenue misses.
Omnicell Inc. (NASDAQ: OMCL): Benchmark raised its Hold rating to Buy and has a $68 target price. The consensus target is $71.89, and shares closed on Monday at $52.96.
Pulmonx Corp. (NASDAQ: LUNG): Wells Fargo’s upgrade to Overweight from Equal Weight included a target price hike to $15 from $10. The consensus target is $12.43. The shares closed almost 6% higher on Monday at $10.99.
Relay Therapeutics Inc. (NASDAQ: RLAY): Oppenheimer reiterated an Outperform rating with a $33 target price objective. The consensus target is $35.45. The stock closed on Monday at $16.56.
Sangamo Therapeutics Inc. (NASDAQ: SGMO): Wedbush’s upgrade was from Neutral to Outperform with a $16 target price. The consensus target is $9.40, The shares closed almost 12% higher on Monday at $2.96. The company posted some solid clinical and revenue data last week.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
